Published 2 years ago • loading... • Updated 2 years ago

Merck COVID-19 pill linked to virus mutations – study (NYSE:MRK)

Summary by Ground News

Lagevrio, the FDA-authorized oral COVID-19 therapy, leads to new mutations in the virus, according to a new study. The researchers in the U.S. and U.K. collaborated with those in the Francis Crick Institute, Imperial College, and the University of Liverpool.

5 Articles

All

Left

Center

Right

South China Morning Post

Center

Merck’s Covid-19 drug linked to new virus mutations, study says

Merck & Co’s Covid-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.

2 years ago·Hong Kong

Read Full Article

Seeking Alpha

Lean Right

Merck COVID-19 pill linked to virus mutations – study (NYSE:MRK)

Lagevrio, the oral COVID-19 therapy developed by Merck (MRK) Ridgeback Biotherapeutics, leads to new mutations in the virus with the potential for further spread. Read the full story here.

2 years ago·United States

Read Full Article

Bloomberg

Lean Left

Merck Covid Drug Linked to New Virus Mutations, Study Says - BNN Bloomberg

Merck & Co.’s Covid-19 pill is giving rise to new mutations of the virus in some patients, according to a study that underscores the risk of trying to intentionally alter the pathogen’s genetic code.

2 years ago·United States

Read Full Article